The efficacy and safety of sequential IL-12/23p40 inhibitor and IL-17A inhibitor in the treatment of moderate to severe plaque psoriasis: A multicenter randomized controlled clinical trial

Start Date03 Aug 2026

Sponsor / Collaborator

Xinhua Hospital

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Aug 2026

Sponsor / Collaborator

The University of California, San Francisco

ChiCTR2600128669

/ SuspendedNot ApplicableIIT

Efficacy and Safety of IL-23p19 Inhibitor Followed by IL-17A Inhibitor in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Controlled Clinical Trial

Start Date01 Apr 2026

Sponsor / Collaborator

Xinhua Hospital

100 Clinical Results associated with Ixekizumab

100 Translational Medicine associated with Ixekizumab

100 Patents (Medical) associated with Ixekizumab

1,214

Literatures (Medical) associated with Ixekizumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Review

Author: Liu, Clive M. ; Merola, Joseph F. ; Cather, Jennifer C. ; Strober, Bruce E. ; Lebwohl, Mark G. ; Armstrong, April W.

OBJECTIVE:

To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events.

METHODS:

Relevant published evidence from real-world studies and clinical trials that met defined criteria was identified through targeted searches of PubMed, supplemented by manual reviews of reference lists and input from authors.

RESULTS:

In real-world studies of patients with treatment failure on anti-IL-17 agents (secukinumab and/or ixekizumab), brodalumab achieved PASI 75, PASI 90, and PASI 100 in 47.8%-81.7%, 40.0%-58.9%, and 28.0%-50.0% of patients, respectively, after 12-16 weeks of treatment. PASI 100 was achieved by 45.5%-63.6% of patients with 26 weeks of brodalumab therapy after anti-IL-12/23, anti-IL-23, or anti-tumor necrosis factor alpha agents in a phase 4 study. Studies with longer-term follow-up have suggested that responses to brodalumab are durable in biologic-experienced patients.

CONCLUSIONS:

Literature evaluated in this narrative review positions brodalumab as a rational, safe, and effective treatment option for adults with moderate to severe plaque psoriasis who have an inadequate response/loss of an initial response to their existing biologic agent.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update

Review

Author: Alajlan, Mohammed Abdulaziz ; Almudaiheem, Hajer Y. ; Al-Omari, Bedor A. ; Eshmawi, Maysa Tariq ; Hamadah, Issam ; Alotaibi, Haifa F. ; Alhazzani, Waleed ; Binamer, Yousef ; Aljedai, Ahmed ; Fatani, Mohammed Ibrahim ; Alzuriqan, Fahad ; Alessa, Dana

BACKGROUND:

Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects approximately 5.3% of the population in the Kingdom of Saudi Arabia (KSA). Thus, we aim to develop updated evidence-based clinical practice guidelines for the management of adults and pediatric patients with moderate-to-severe plaque psoriasis in the KSA.

METHODS:

These guidelines followed the "Grading of Recommendations, Assessment, Development, and Evaluation" (GRADE) methodology. We conducted a systematic literature review of PubMed, EMBASE, and the Cochrane Library for high-quality evidence published between 2020 and 2026. The panel developed 31 PICO questions that address key treatment considerations for moderate-to-severe psoriasis.

RESULTS:

We established 27 evidence-based recommendations and 4 good-practice statements addressing key aspects of moderate-to-severe psoriasis management. These guidelines strongly recommend adopting the Psoriasis Area and Severity Index (PASI) 90 as the primary treatment goal over PASI 75. For adult patients, the guidelines recommend biologic therapies, including interleukin (IL)-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, and tumor necrosis factor (TNF)-α inhibitors, for better disease control. For pediatric patients, the guidelines recommend early initiation of biologic therapy, with etanercept, secukinumab, ixekizumab, and adalimumab as preferred options.

CONCLUSION:

These Saudi national guidelines offer a comprehensive, evidence-based framework for managing moderate-to-severe psoriasis in adults and pediatric patients.

01 Nov 2026·Arthritis & Rheumatology

Letter

Author: Cardoso, Anabela ; Sun, Luna ; Genovese, Mark C. ; Ogdie, Alexis ; Fischer, Peter ; Merola, Joseph F. ; Kartman, Cynthia E.

143

News (Medical) associated with Ixekizumab

30 Oct 2026

·www.biopharmadive.com

Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies results and how theyre being received by investors. Today, were offering insight into the latest numbers from Eli Lilly, Novartis and GSK.Lillys unwavering momentumEli Lilly blew past Wall Street analysts forecasts on Thursday, posting third-quarter revenue that topped consensus projections by 8% as its widely popular diabetes and obesity drugs Mounjaro and Zepbound once again beat expectations.Lilly hiked its full-year guidance by $5 billion, too, producing a beat-and-raise quarter that sent shares of the Indiana-based drugmaker surging as much as 9% Thursday.For Lilly, the report appeared to put to rest investor concerns that Medicares Bridge program, which was implemented on July 1, might impact its obesity drug revenue. Investors were also anxious about the fast-changing pricing dynamics in the market for weight-loss medicines.The “strong execution across the GLP-1 franchise“ is “more than offsetting pricing pressure,“ wrote RBC Capital Markets analyst Trung Huynh, in a Thursday client note.Lilly said it recorded third quarter revenue of $24.4 billion, above a Wall Street consensus of $22.7 billion. Mounjaro accounted for $10.7 billion of that total and Zepbound $5.4 billion. Both topped analyst forecasts of $10 billion and $5 billion, respectively.The only piece of Lilly's metabolic franchise to miss projections was the new obesity pill Foundayo, which generated $184 million in sales $44 million short of Wall Streets estimate. And beyond that business, the one medicine that didnt sell as well as investors had hoped was the psoriasis drug Taltz, which posted revenue $48 million below consensus at $856 million.The company now expects full-year revenue to reach $91 billion to $92 billion, compared with $85 billion to $87 billion in the second quarter and $80 billion to $83 billion at the beginning of the year.Lilly said it has now claimed 63% of the U.S. market and 58% of the overseas market for drugs modulating GLP-1 and other metabolic hormones called incretins. It will need to continue to add to its lead, as patents for Novos rival drugs Ozempic and Wegovy will begin to expire in 2031 and 2032.But for now, the performance of Lillys dominant franchise should quell investor concerns over GLP-1 growth in the near term, Cantor Fitzgerald analyst Carter Gould wrote in a client note. Jonathan GardnerNovartis quick reboundNovartis has spent much of the past two years trying to convince investors it has a solid plan for surviving one of the pharmaceutical industrys steepest patent cliffs. But a couple major setbacks this past quarter sowed doubt about its prospects.In a span of one week in September, the Swiss pharmaceutical firm delivered disappointing results from two trials that have been seen by investors and analysts as critical to its future. First, a cardiovascular disease medicine called pelacarsen once viewed as a possible multibillion-dollar product failed to protect heart health in a massive late-stage study. Then, del-desiran, a treatment it picked up in a $12 billion takeover of Avidity Biosciences, fell short in a Phase 3 study in a rare muscle disorder.The two study failures caused shares to slide nearly 15%, erasing tens of billions of dollars in market value. And del-desirans stumble led Novartis to write off $1.9 billion of the Avidity deal, even though the company hasnt yet given up on the drug. The charge was primarily driven by the time line shifting out and the additional clinical work that needs to be completed, CEO Vas Narasimhan told analysts this week. Novartis wont seek U.S. approval of pelacarsen, and isnt yet sure whether itll advance another RNA-based drug similarly designed to lower levels of a protein particle called LP(a).Yet despite those stumbles, the big drugmakers share price has largely rebounded and pushed higher following the latest earnings report. Third-quarter net sales hit $14.5 billion, just ahead of Wall Street estimates, thanks in large part to older drugs like Cosentyx, Entresto, Zolgensma and Ilaris. Novartis, in turn, slightly raised its 2026 outlook, something that analysts at Jefferies said should be well received in the current market backdrop.Novartis breast cancer drug Kisqali and multiple sclerosis treatment Kesimpta also helped deliver a solid third quarter, RBC analyst Huynh wrote in a note to clients after the Tuesday earnings call. Overall, the company delivered the clean quarter investors were looking for following a mixed quarter of pipeline readouts.A pill Novartis is developing for multiple sclerosis succeeded in a pair of Phase 3 trials and could, if approved, hit peak annual sales of $4 billion in that indication in the years to come, the company projected. And though sales of its prostate cancer drug Pluvicto slowed in the third quarter, theyre expected to ramp up next year, Novartis said.We do expect to get back to where we were, dynamic growth, in 2027, Narasimhan said. Gwendolyn WuGSKs waiting gameGSK has made notable progress toward a plan to reinvent itself ahead of a sizable patent cliff. Multiple recent drug approvals, along with the steady progress of a growing oncology pipeline, have fortified its chances to rake in 40 billion in annual revenue by 2031.In some respects, the numbers the British pharma reported on Wednesday suggested it has begun to see some returns on that strategy. Overall third-quarter sales rose by 5%, primarily driven by the performance of its specialty medicines, and were broadly in line with Wall Streets expectations. GSK reaffirmed its full-year financial outlook, too.Still, investors responded to the news by sending shares sliding by 5%. The headline numbers could be masking underlying weakness, wrote RBC Capital Markets analyst Trung Huynh. And GSK is also entering a period of limited earnings momentum, fewer readouts and questions surrounding its HIV business, added Jefferies analyst Michael Leuchten.One lingering issue is an ongoing decline in vaccine sales, which missed analyst benchmarks in part due to the performance of the shingles shot Shingrix and the respiratory syncytial virus vaccine Arexvy. But some analysts also pointed to doubts about other pipeline products important to GSKs future.The long-acting asthma drug Exdensur, touted by GSK as a blockbuster-to-be, fell well short of expectations despite an increase in commercial coverage from 18% to 43%, Huynh wrote. The drug recorded 27 million in sales in the third quarter, and its launch will have to accelerate substantially to reach 2027s consensus target of 373 million, he added.That number didnt alarm the company. On an earnings call, GSKs President of Global Product Strategy, Nina Mojas, said there has already been a significant increase in new prescribers and that the summertime tends to be particularly slow in terms of patient visits. We do expect to see a change in trend from now on, she added.Investors are also anxious about another pending readout. The company is testing a longer-acting version of its preventive HIV drug cabotegravir and has data in hand, but hasnt yet shared it. An analysis is ongoing, and the company intends to bring the results to regulators by years end, said corporate development chief David Redfern.Obviously, we will update the market once that analysis is complete, he added. Delilah Alvarado '

Phase 3VaccineClinical Result

29 Oct 2026

·www.biospace.com

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates. Q3 2026 EPS increased by 16% to $7.22 on a reported basis and increased by 7% to $7.48 on a non-GAAP basis. Q3 2026 reported and non-GAAP EPS included $4.57 of acquired IPR&D charges compared to $0.71 in Q3 2025. Increased the midpoint of our 2026 full-year revenue guidance by $5.5 billion to be in the range of $91.0 to $92.0 billion and raised underlying non-GAAP EPS guidance for the full year by $4.07 at the midpoint, which was more than offset by $4.57 of acquired IPR&D charges from Q3 business development activity, resulting in an updated range of $35.00 to $36.00. Regulatory progress included U.S. FDA approvals of Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes; Onswik, a once-weekly basal insulin for adults with type 2 diabetes; Inluriyo with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer; and an expanded indication for Jaypirca in adults with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Pipeline highlights included positive topline results from a head-to-head Phase 3 trial of retatrutide versus Ozempic 2 mg in adults with type 2 diabetes, Phase 3 results from Ebglyss in moderate-to-severe hand and foot atopic dermatitis and Phase 2 results from EloraTZP in adults with obesity and type 2 diabetes, with Phase 3 trials to start in Q4 2026. Business development activity in Q3 2026 included the completed acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions. Subsequent to quarter end, we completed the acquisition of Merida Biosciences, to advance treatments for serious autoimmune and allergic diseases. INDIANAPOLIS , Oct. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2026 and provided updated 2026 financial guidance. "Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook," said David A. Ricks, Lilly chair and CEO. "Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience. To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions in Texas and Virginia. Lilly is executing well across the value chain, and our potential for impact on human health continues to expand." Financial Results $ in millions, except per share data Third-Quarter 2026 2025 % Change Revenue $ 24,397 $ 17,601 39 % Net income – Reported 6,451 5,583 16 % Earnings per share – Reported (1) 7.22 6.21 16 % Net income – Non-GAAP 6,679 6,312 6 % Earnings per share – Non-GAAP (1) 7.48 7.02 7 % (1) Q3 2026 reported and non-GAAP EPS included $4.57 of acquired IPR&D charges compared to $0.71 in Q3 2025 A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)." Third-Quarter Reported Results In Q3 2026, worldwide revenue was $24.4 billion, an increase of 39% compared with Q3 2025, driven by a 53% increase in volume, partially offset by a 15% decrease in realized prices. Key Products 1 revenue grew to $17.1 billion in Q3 2026, led by Mounjaro and Zepbound. Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 100% in Q3 2026 compared to Q3 2025. Revenue in the U.S. increased 34% to $15.1 billion, driven by a 41% increase in volume, partially offset by a 7% decrease in realized prices. The increase in U.S. volume was driven by Zepbound and Mounjaro. The decline in realized prices was primarily driven by Zepbound, partially offset by adjustments to estimates for rebates and discounts. Revenue outside the U.S. increased 47% to $9.3 billion, driven by a 76% increase in volume, partially offset by a 29% decrease in realized prices. The volume increase outside the U.S. was driven by Mounjaro. Jardiance revenue outside the U.S. included sales-based milestones of $410 million in Q3 2026 and $200 million in Q3 2025, associated with the company's collaboration with Boehringer Ingelheim. Additionally, Q3 2025 revenue included $180 million associated with the divestiture of the rights to Cialis in select markets outside of the U.S. Lower realized prices outside the U.S. were driven primarily by the inclusion of Mounjaro on the National Reimbursement Drug List (NRDL) in China. Gross margin increased 40% to $20.5 billion in Q3 2026. Gross margin as a percent of revenue was 83.9%, an increase of 1.0 percentage points versus the same quarter last year. The increase was primarily driven by favorable product mix and improved cost of production, partially offset by lower realized prices. In Q3 2026, research and development expenses increased 23% to $4.2 billion, or 17% of revenue, driven by continued investments in the company's early and late-stage portfolio. Marketing, selling, and administrative expenses increased 14% to $3.1 billion in Q3 2026, primarily driven by promotional efforts supporting ongoing and planned launches. In Q3 2026, the company recognized acquired in-process research and development (IPR&D) charges of $4.2 billion compared with $656 million in Q3 2025. The Q3 2026 charges primarily related to the acquisitions of AtaiBeckley Inc. and Curevo Inc. The effective tax rate was 23.3% in Q3 2026 compared with 22.8% in Q3 2025, primarily driven by the unfavorable tax impact of nondeductible acquired IPR&D charges, with a larger impact occurring in 2026. The Q3 2025 effective tax rate was also unfavorably impacted by U.S. tax law changes. In Q3 2026, net income and earnings per share (EPS) were $6.5 billion and $7.22, respectively, compared with net income of $5.6 billion and EPS of $6.21 in Q3 2025. EPS in Q3 2026 and Q3 2025 included acquired IPR&D charges of $4.57 and $0.71, respectively. 1 The Company currently defines Key Products as Ebglyss, Foundayo, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound. Third-Quarter Non-GAAP Measures On a non-GAAP basis, Q3 2026 gross margin increased 40% to $20.6 billion. Gross margin as a percent of revenue was 84.4%, an increase of 0.8 percentage points versus the same quarter last year. The increase was primarily driven by favorable product mix and improved cost of production, partially offset by lower realized prices. The non-GAAP effective tax rate was 24.0% in Q3 2026 compared with 17.7% in Q3 2025, primarily driven by the unfavorable tax impact of nondeductible acquired IPR&D charges, with a larger impact occurring in 2026. On a non-GAAP basis, Q3 2026 net income and EPS were $6.7 billion and $7.48, respectively, compared with net income of $6.3 billion and EPS of $7.02 in Q3 2025. Non-GAAP EPS in Q3 2026 and Q3 2025 included acquired IPR&D charges of $4.57 and $0.71, respectively. For further detail on non-GAAP measures, see the reconciliation below as well as the "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)" table later in this press release. Third-Quarter 2026 2025 % Change Earnings per share (reported) $ 7.22 $ 6.21 16 % Amortization of intangible assets .11 .11 Asset impairment, restructuring and other special charges .18 .36 Net gains on investments in equity securities (.04) (.04) U.S. Tax Law Change — .39 Earnings per share (non-GAAP) $ 7.48 $ 7.02 7 % Acquired IPR&D 4.57 .71 NM Numbers may not add due to rounding NM - not meaningful Selected Revenue Highlights (Dollars in millions) Third-Quarter Year-to-Date Selected Products 2026 2025 % Change 2026 2025 % Change Mounjaro $ 10,723 $ 6,515 65 % $ 29,328 $ 15,556 89 % Zepbound (1) 5,352 3,588 49 % 14,440 9,281 56 % Jaypirca 228 143 59 % 585 358 63 % Ebglyss 202 127 59 % 548 274 100 % Kisunla 193 70 175 % 484 141 NM Omvoh 114 65 76 % 296 177 67 % Foundayo 184 — NM 281 — NM Inluriyo 73 — NM 183 — NM Total Revenue 24,397 17,601 39 % 67,170 45,887 46 % (1) Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. NM - not meaningful Mounjaro For Q3 2026, worldwide Mounjaro revenue increased 65% to $10.7 billion. U.S. revenue was $5.0 billion, an increase of 41%, reflecting strong demand. Revenue outside the U.S. increased 93% to $5.7 billion primarily driven by volume growth, partially offset by lower realized prices driven by the addition of Mounjaro on the NRDL in Q1 2026. Zepbound For Q3 2026, U.S. Zepbound revenue increased 48% to $5.3 billion, primarily driven by strong demand, partially offset by lower realized prices. Lilly shared numerous updates recently on key regulatory, clinical, business development, and other events, including: Regulatory Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL ( announcement ) FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata ( announcement ) U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes ( announcement ) U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer ( announcement ) FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes ( announcement ) Clinical Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial ( announcement ) New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer ( announcement ) Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 ( announcement ) Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis ( announcement ) New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year ( announcement ) New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity ( announcement ) Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study ( announcement ) Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes ( announcement ) New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis ( announcement ) Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes ( announcement ) New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity ( announcement ) Other Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets ( announcement ) Lilly breaks ground in Richmond to expand American manufacturing of next- generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020 ( announcement ) Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs ( ann ouncement ) Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 ( announce ment ) Lilly completes acquisition of AtaiBeckley to advance therapies for treatment- resistant depression and other mental health conditions ( announcement ) Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases ( announcement ) Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study ( announcement ) Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market ( announcement ) For information on important public announcements, visit the news section of Lilly's website. 2026 Financial Guidance In addition to providing guidance for GAAP revenue, Lilly provides guidance for certain non-GAAP measures. The following table summarizes the company's updated full-year 2026 non-GAAP financial guidance, reflecting strong underlying performance across our portfolio. The first three quarters of 2026 also benefited from sales-based milestones and adjustments to estimates for rebates and discounts. In addition to updates to Revenue and Performance Margin guidance, EPS guidance has been adjusted to reflect an increase of $4.07 (at the midpoint of the range), offset by $4.57 associated with the Q3 acquired IPR&D charges from recent business development activity: Prior Updated Revenue $85 to $87 billion $91 to $92 billion Performance Margin (1)(2) 49.0% to 50.5% 52.0% to 52.5% Tax Rate (1)(3) 18% to 19% 19% to 20% Earnings per Share (1)(3)(4) $35.50 to $36.50 $35.00 to $36.00 (1) Lilly does not provide reconciliations of forward-looking non-GAAP measures to the most directly comparable GAAP measures because comparable GAAP measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for a reconciliation. In particular, Lilly cannot reasonably predict certain items including net gains and losses on equity securities, asset impairment, acquisition or divestiture-related items, or restructuring and other adjustments, without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on Lilly's reported results in accordance with GAAP. See Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) table below for additional Non-GAAP information. (2) The company defines performance margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue. (3) Guidance does not include acquired in-process research and development (IPR&D) incurred after September 30, 2026. (4) Assumes shares outstanding of approximately 894 million and foreign currency exchange rate assumptions of 1.13 (Euro), 157 (Yen) and 6.7 (Yuan) Webcast of Conference Call As previously announced, investors and the general public can access a live webcast of the Q3 2026 financial results conference call through a link on Lilly's website at investor.lilly.com/webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website. Non-GAAP Financial Measures Certain financial information is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Historical non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2026 financial guidance (other than revenue) is provided on a non-GAAP basis, as described in "2026 Financial Guidance" above. Non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news. F-LLY Cautionary Statement Regarding Forward-Looking Statements This press release and the related attachments contain management's intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "estimate", "project", "intend", "expect", "believe", "target", "plan", "anticipate", "may", "could", "aim", "seek", "will", "continue", and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals and the ability of the company's clinical trials to meet expectations; the impact and uncertain outcome of acquisitions and business development transactions and related costs; intense competition affecting the company's products, pipeline, or industry; market uptake of launched products and indications; continued pricing pressures and the impact of actions of governmental and private actors affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; the implementation of the company's voluntary agreement with the U.S. government related to drug pricing and access; developments or uncertainties related to the company's or competitive products, including as may relate to safety or efficacy concerns; dependence on relatively few products or product classes for a significant percentage of the company's total revenue and a consolidated supply chain; the expiration of intellectual property protection for certain of the company's products and competition from generic and biosimilar products; the company's ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data and violations of data protection laws or regulations; issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to the company's and third-party facilities; reliance on third-party relationships and outsourcing arrangements; the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; fluctuations in foreign currency exchange rates, changes in interest rates and inflation or deflation; significant and sudden declines or volatility in the trading price of the company's common stock and market capitalization; litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property; changes in tax law and regulations, tax rates, or events that differ from the company's assumptions related to tax positions; regulatory changes, developments, and uncertainty; regulatory oversight and actions regarding the company's operations and products; regulatory compliance problems or government investigations; risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products; actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; asset impairments and restructuring charges; and changes in accounting and reporting standards. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements contained in this press release and the related attachments, which, except as otherwise noted, speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements contained in this press release and the related attachments to reflect events or circumstances after the date of this release. Website Information The information contained on, or that may be accessed through, our website or any third-party website is not incorporated by reference into, and is not a part of, this earnings release. Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Eli Lilly and Company Operating Results (Unaudited) – REPORTED (Dollars in millions, except per share data; numbers may not add due to rounding) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 % Chg. 2026 2025 % Chg. Revenue $ 24,397 $ 17,601 39 % $ 67,170 $ 45,887 46 % Cost of sales 3,933 3,008 31 % 10,778 7,680 40 % Research and development 4,247 3,466 23 % 11,576 9,536 21 % Marketing, selling, and administrative 3,125 2,741 14 % 9,489 7,963 19 % Acquired IPR&D 4,181 656 NM 7,541 2,381 NM Asset impairment, restructuring and other special charges 303 365 (17) % 1,285 400 NM Operating income 8,608 7,365 17 % 26,501 17,927 48 % Net interest income (expense) (316) (114) (843) (519) Net other income (expense) 114 (18) 845 57 Other income (expense) (202) (132) 53 % 2 (462) (100) % Income before income taxes 8,406 7,233 16 % 26,503 17,465 52 % Income tax expense 1,955 1,650 18 % 5,561 3,463 61 % Net income $ 6,451 $ 5,583 16 % $ 20,942 $ 14,002 50 % Earnings per share - diluted $ 7.22 $ 6.21 16 % $ 23.42 $ 15.56 51 % Dividends paid per share $ 1.73 $ 1.50 15 % $ 5.19 $ 4.50 15 % Weighted-average shares outstanding (thousand) - diluted 893,439 898,804 894,371 899,734 NM – not meaningful Eli Lilly and Company Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) (Dollars in millions, except per share data; numbers may not add due to rounding) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Gross Margin - As Reported $ 20,464 $ 14,593 $ 56,392 $ 38,207 Increase for excluded items: Amortization of intangible assets (Cost of sales) (1) 128 119 381 364 Gross Margin - Non-GAAP $ 20,592 $ 14,712 $ 56,773 $ 38,571 Gross Margin as a percent of revenue - As Reported 83.9 % 82.9 % 84.0 % 83.3 % Gross Margin as a percent of revenue - Non-GAAP (2) 84.4 % 83.6 % 84.5 % 84.1 % 1. Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties. 2. Non-GAAP gross margin as a percent of revenue reflects the gross margin effects of the adjustments presented above. Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) (Dollars in millions, except per share data; numbers may not add due to rounding) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Net income - Reported $ 6,451 $ 5,583 $ 20,942 $ 14,002 Increase (decrease) for excluded items: Amortization of intangible assets (Cost of sales) (1) 128 119 381 364 Asset impairment, restructuring and other special charges (2) 303 365 1,285 400 Net (gains) losses on investments in equity securities (Other income/expense) (47) (48) (571) 6 U.S. Tax Law Change (Income taxes) (3) — 350 — 350 Corresponding tax effects (Income taxes) (156) (57) (202) (126) Net income - Non-GAAP $ 6,679 $ 6,312 $ 21,835 $ 14,996 Effective tax rate - Reported 23.3 % 22.8 % 21.0 % 19.8 % Effective tax rate - Non-GAAP (4) 24.0 % 17.7 % 20.9 % 17.8 % Earnings per share (diluted) - Reported $ 7.22 $ 6.21 $ 23.42 $ 15.56 Earnings per share (diluted) - Non-GAAP $ 7.48 $ 7.02 $ 24.41 $ 16.67 1. Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties. 2. For the three and nine months ended September 30, 2026, excludes a charge primarily related to a partial impairment of an intangible asset associated with a molecule in development. For the nine months ended September 30, 2026 and the three and nine months ended September 30, 2025, excludes charges related to acquisition and integration costs associated with the closing of our acquisitions and charges related to litigation matters. 3. Relates to adjusting our income tax provision for prior periods and remeasuring our deferred tax assets and liabilities. 4. Non-GAAP tax rate reflects the tax effects of the adjustments presented above. Refer to: Megan MacCauley; maccauley_megan@lilly.com (Media) Mike Czapar; czapar_michael_c@lilly.com (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company

Clinical ResultDrug ApprovalPhase 3AcquisitionFinancial Statement

09 Oct 2026

·www.prnewswire.com

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. The prespecified analysis, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, provides new insights suggesting an immunometabolic relationship between psoriasis and obesity. These data showed that when Taltz and Zepbound were used together, changes were observed in more psoriasis disease-associated and metabolic biomarkers compared to Taltz monotherapy. In the U.S., approximately 61% of people with psoriasis also have obesity or overweight with at least one weight-related comorbidity.1 "People living with psoriasis and obesity carry a compounded burden that extends beyond what is visible, yet these conditions are too often viewed through separate treatment lenses," said Mark Genovese, M.D., senior vice president of Lilly Immunology development. "The broader biomarker changes observed with Taltz and Zepbound, including those associated with skin clearance, may point to a meaningful relationship between immune and metabolic biology. Along with previously reported clinical outcomes, these findings support a more comprehensive approach to psoriasis care that also addresses obesity for people managing both conditions." This analysis examined circulating proteins and gene expression in the blood to better understand the biological change observed when patients were treated concomitantly with Taltz and Zepbound vs. Taltz alone. At Week 36, observed changes in psoriasis-specific, immune and metabolic biomarkers in both the Taltz and Zepbound and Taltz monotherapy treatment arms were consistent with the known biological effects of each medicine when used for their approved indications. Notably, Taltz and Zepbound used together were associated with broader biomarker responses compared to Taltz alone as early as Week 12. This included changes in more proteins (482 vs. 140 differentially expressed proteins) and genes (467 vs. 16 differentially expressed genes) by Week 36. Further, the analysis showed greater reductions in inflammatory immune activity with Taltz and Zepbound compared with Taltz alone, including changes related to neutrophils, a type of immune cell involved in inflammation. Changes in a subset of neutrophil-associated markers mediated a portion of the additional Psoriasis Area and Severity Index (PASI) response seen with Taltz and Zepbound vs. Taltz alone. "This analysis provides new insights into the potential connected immune and metabolic biology in people with psoriasis and obesity," said James G. Krueger, M.D., Ph.D., Professor and Laboratory Head, The Rockefeller University. "What is most compelling is these findings identified differences in inflammatory pathways when patients received concomitant treatment with Taltz plus Zepbound for both conditions. These data at the intersection of psoriasis and obesity highlight immunometabolic health as an important area for continued scientific research." These data follow previously reported results from TOGETHER-PsO, which showed that Taltz and Zepbound used together delivered superior skin clearance and clinically meaningful weight reduction compared with Taltz alone at the Week 36 primary endpoint. Improvements were maintained or further improved through Week 52, with safety consistent with the known profile of each respective medicine. About the TOGETHER-PsO trial TOGETHER-PsO (NCT06588283) is a 52-week Phase 3b, randomized, multicenter, assessor-blinded, open-label study assessing the efficacy and safety of concomitant administration of Taltz and Zepbound compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight (BMI ≥30 kg/m², or ≥27 to <30 kg/m²) with at least one additional weight-related comorbid condition. A total of 274 participants were randomized 1:1 to receive either Taltz alone or concomitantly with Zepbound, both administered subcutaneously. Patients in both arms received counseling on a reduced-calorie diet and increased physical activity. The primary endpoint is to assess the proportion of participants achieving both Psoriasis Area and Severity Index (PASI) 100 and ≥10% weight reduction at Week 36. About Taltz (ixekizumab) Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines. Taltz is approved to treat adults with active psoriatic arthritis and adults and children 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Additionally, Taltz is approved for adults with active ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. About Zepbound (tirzepatide) injection Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity. TALTZ INDICATIONS AND SAFETY SUMMARY Taltz® (tȯl-ts) is an injectable medicine used to treat: People 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). Adults with active psoriatic arthritis. Adults with active ankylosing spondylitis. Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. It is not known if Taltz is safe and effective in children for conditions other than plaque psoriasis or in children under 6 years of age. Warnings - Taltz affects the immune system. It may increase your risk of infections, some people have had serious infections, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized from these infections. Do not use Taltz if you have any symptoms of infection, unless your doctor tells you to. If you have a symptom after starting Taltz, call your doctor right away. Your doctor should check you for TB before you start Taltz, and watch you closely for signs of TB during and after treatment with Taltz. If you have TB, or had it in the past, your doctor may treat you for it before you start Taltz. Do not use Taltz if you have had a serious allergic reaction to ixekizumab or any other ingredient in Taltz, such as: swelling of your eyelids, lips, mouth, tongue or throat, trouble breathing, feeling faint, throat or chest tightness, or skin rash. Get emergency help right away if you have any of these reactions. See the Medication Guide that comes with Taltz for a list of ingredients. Severe skin reactions that look like eczema can happen during treatment with Taltz from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with Taltz if you develop severe skin reactions. Tell your doctor if you have any of the following: redness or rash, itching, patches, your skin is dry or feels like leather, blisters or abrasions that ooze or become crusty, small bumps or plaques with scale or crusting. Crohn's disease or ulcerative colitis (inflammatory bowel disease) can start or get worse with Taltz use. Tell your doctor if you have any of these symptoms or if they get worse: stomach pain, diarrhea, and weight loss. You should not get live vaccines while taking Taltz. You should get the vaccines you need before you start Taltz. Common side effects The most common side effects of Taltz include: Injection site reactions Nausea Upper respiratory infections Fungal skin infections Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or . Before using Before you use Taltz, review these questions with your doctor: Are you being treated for an infection? Do you have an infection that does not go away or keeps coming back? Do you have TB or have you been in close contact with someone with TB? Do you have possible symptoms of an infection such as fever, cough, sores, diarrhea, or other symptoms? Ask your doctor about other possible symptoms. Do you have Crohn's disease or ulcerative colitis? Tell your doctor if: You need any vaccines or have had one recently. You take prescription or over-the-counter medicines, vitamins, or herbal supplements. You are pregnant or planning to become pregnant. It is not known if Taltz can harm an unborn baby. Pregnancy Exposure Registry: There is a pregnancy registry to collect information about women who are exposed to Taltz during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become pregnant while taking Taltz, you are encouraged to enroll in the pregnancy registry by calling 1-800-284-1695 or by visiting online at . You are breastfeeding or planning to breastfeed. It is not known if Taltz passes into breastmilk. How to take See the instructions for use that come with Taltz. There you will find information about how to store, prepare, and inject Taltz. Adults may self-inject after receiving training from a healthcare provider. For children 6 to 17 years of age: If your child's healthcare provider decides that you may give Taltz injections at home, you should receive training on the right way to prepare and inject Taltz. Do not try to give Taltz to your child until you have been shown how to inject Taltz. Children should not inject themselves with Taltz. You or an adult caregiver should prepare and give Taltz injections to your child. Learn more Taltz is a prescription medicine available as a 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection. For more information, call 1-800-545-5979 or go to taltz.lilly.com. This summary provides basic information about Taltz but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Taltz and how to take it. Your doctor is the best person to help you decide if Taltz is right for you. IX CON BS 20AUG2024 U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with: obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider. Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen ® : Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them. Zepbound may cause serious side effects, including: Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away. Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away. Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools. Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back. Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat. Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery. Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound. Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures. Common side effects The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away. Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or . Before using Zepbound Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider: ❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food? ❑ Do you take diabetes medicines, such as insulin or sulfonylureas? ❑ Do you have a history of diabetic retinopathy? ❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)? ❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements? ❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound. Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit . How to take Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection. Learn more Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to . This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you. ZP CON BS 01SEP2026 Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for psoriasis and Zepbound (tirzepatide) as a treatment for adults with obesity or overweight, and potential comprehensive treatment strategies for patients with psoriasis and obesity, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date, or that Lilly will execute its strategies as planned. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. References and endnotes Armstrong et al, Addressing the Obesity-Psoriasis Connection: Prevalence, Incidence, and Comorbidity Insights from a Large US Population of 19.9 Million (2018-2024). Presented at Maui Derm, 2026. SOURCE Eli Lilly and Company 21% more press release views with Request a Demo

Clinical ResultPhase 3Drug Approval

100 Deals associated with Ixekizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10071	Ixekizumab	L04AC13	DB11569

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Spondylarthritis	Canada	Eli Lilly & Co.	11 Aug 2016
Erythrodermic psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis vulgaris	Japan	Eli Lilly Japan KK	04 Jul 2016
Pustular psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Ankylosing Spondylitis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enthesitis-Related Arthritis	NDA/BLA	European Union	Eli Lilly & Company (Ireland) Ltd.	24 Jul 2025
Juvenile Idiopathic Arthritis	NDA/BLA	European Union	Eli Lilly & Company (Ireland) Ltd.	24 Jul 2025
Obesity	Phase 3	United States	Eli Lilly & Co.	24 Sep 2024
Uveitis, Anterior	Phase 3	Japan	Eli Lilly Japan KK	16 Aug 2016
Back Pain	Phase 3	Japan	Eli Lilly Japan KK	19 May 2016
Sacroiliitis	Phase 3	Japan	Eli Lilly Japan KK	19 May 2016
Tuberculosis	Phase 3	Japan	Eli Lilly Japan KK	19 May 2016
Chronic large plaque psoriasis	Phase 3	United States	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Japan	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Australia	Eli Lilly & Co.	16 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2026	Not Applicable	Arthritis, Psoriatic	134	TirzepatideIxekizumab + TirzepatideIxekizumabe	fzmykzqjzo(ygofohnkby) = jzjvvrzjlp aqsyohznth (fibujdjjrj ) View more	Positive	06 Nov 2026
ACR2026	Not Applicable	Arthritis, Psoriatic	200	Bimekizumab	yyeabrsxlo(qznlyhutrp) = bapnztfabn jwaekcssnb (fnxmwhlmok )	Positive	06 Nov 2026
				Secukinumab/Ixekizumab	yyeabrsxlo(qznlyhutrp) = cdlxcqkile jwaekcssnb (fnxmwhlmok )
NCT06588296 (TOGETHER-PsA, ACR2026)	Phase 3	Arthritis, Psoriatic	271	Ixekizumab Plus Tirzepatide	xjcmafhjpn(irzecxweqi) = batotzrgxy dcxtreuwki (atauarswhm )	Positive	06 Nov 2026
				Ixekizumab	xjcmafhjpn(irzecxweqi) = kkvmirbrhb dcxtreuwki (atauarswhm )
TOGETHER-PsO (ACR2026)	Phase 3	Psoriasis \| Arthritis, Psoriatic	545	Ixekizumab with Tirzepatide	aeipfsbquu(wzsbkmtdre) = significantly reduced qvehosutws (lefevtlvhc ) View more	Positive	06 Nov 2026
NCT06588296 (TOGETHER-PsA, ACR2026)	Phase 3	Arthritis, Psoriatic	271	Ixekizumab + Tirzepatide	iokuxekpri(odxdlbgrpx) = haltwdmgkr qilvyxvuyp (nzkxrfsmqb )	Positive	06 Nov 2026
				Ixekizumab	-
NCT06588283 (Pubmed \| JAMA Dermatol)	Phase 3	Psoriasis	274	Ixekizumab plus Tirzepatide	jnipsexqkv(fuxfissbbd) = oazdlgvnfr nlwcgteytd (qlxwkmhuuf ) View more	Positive	01 Jul 2026
				Ixekizumab (Diet and exercise adjunct)	jnipsexqkv(fuxfissbbd) = wbpfefvdaf nlwcgteytd (qlxwkmhuuf ) View more
NCT06588296 (TOGETHER-PSA, EULAR2026)	Phase 3	Arthritis, Psoriatic	271	IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE	mbaaptttpd(epnzhjrijc) = qftbyshvvk lumwioevvb (bkoxlqirgr ) View more	Positive	11 Jun 2026
				IXEKIZUMAB	mbaaptttpd(epnzhjrijc) = zdulxyfljh lumwioevvb (bkoxlqirgr ) View more
EULAR2026	Not Applicable	Ankylosing Spondylitis	1,836	Secukinumab	xeoohbetfo(ccuawkwvpd) = kxnupybydq pgpwzfxumj (rgeumvegdg )	Positive	11 Jun 2026
				Ixekizumab	xeoohbetfo(ccuawkwvpd) = uvxnpdnjds pgpwzfxumj (rgeumvegdg )
DDW2026	Not Applicable	Psoriasis \| Arthritis, Psoriatic \| Spondylarthritis	191	Secukinumab	tmukqzdmuz(oiqmhyrwun) = sirquhuear tgoiagugkw (vgyudttogy ) View more	Positive	02 May 2026
NCT04527380 (COSPIRIT-JIA, Pubmed \| Lancet Rheumatol)	Phase 3	Enthesitis-Related Arthritis \| Arthritis, Psoriatic	101	Ixekizumab (biological DMARD naive)	nqzccywmme(pyollxpgpd) = alyrggncqd vsexvfbrrk (xtalqyvcjx, 82.4 - 97.6)	Positive	01 May 2026
				Ixekizumab (biological DMARD experienced)	nqzccywmme(pyollxpgpd) = bqkujwxqga vsexvfbrrk (xtalqyvcjx, 70.7 - 100.0)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis